https://dasherneuroscience.com/wp-content/uploads/2026/03/cropped-favicon.png
512
512
cjhuang
/wp-content/uploads/2026/03/LOGO_Primary.png
cjhuang2026-10-15 15:29:072026-10-15 15:34:25YA-101 Receives Bronze Award (Pharmaceutical Category) at the 2026 National Pharmaceutical Technology & Research Development AwardDasher Neuroscience Press Releases
Breaking News and Milestones
Corporate News
https://dasherneuroscience.com/wp-content/uploads/2026/03/cropped-favicon.png
512
512
cjhuang
/wp-content/uploads/2026/03/LOGO_Primary.png
cjhuang2026-10-15 15:29:072026-10-15 15:34:25YA-101 Receives Bronze Award (Pharmaceutical Category) at the 2026 National Pharmaceutical Technology & Research Development Award
https://dasherneuroscience.com/wp-content/uploads/2026/03/cropped-favicon.png
512
512
cjhuang
/wp-content/uploads/2026/03/LOGO_Primary.png
cjhuang2026-09-11 10:44:062026-09-11 10:44:06Dasher Neuroscience to Attend BioJapan 2026 Partnering
https://dasherneuroscience.com/wp-content/uploads/2026/03/cropped-favicon.png
512
512
cjhuang
/wp-content/uploads/2026/03/LOGO_Primary.png
cjhuang2026-09-11 10:09:252026-09-11 10:09:25Dasher Neuroscience to Exhibit at MDS Congress 2026Clinical and Research Updates
https://dasherneuroscience.com/wp-content/uploads/2026/03/cropped-favicon.png
512
512
cjhuang
/wp-content/uploads/2026/03/LOGO_Primary.png
cjhuang2026-07-29 11:34:102026-07-29 11:34:10Dasher Neuroscience Completes Patient Enrollment in Phase 2 Global Clinical Trial of Lead AI Drug Candidate YA-101 for Multiple System Atrophy (MSA)
https://dasherneuroscience.com/wp-content/uploads/2026/03/favicon.png
512
512
tflo
/wp-content/uploads/2026/03/LOGO_Primary.png
tflo2026-04-14 14:52:442026-07-14 16:48:30YA-101 Granted Orphan Drug Designation by the EU EMA for the Treatment of Multiple System Atrophy
https://dasherneuroscience.com/wp-content/uploads/2026/03/favicon.png
512
512
tflo
/wp-content/uploads/2026/03/LOGO_Primary.png
tflo2026-04-14 14:51:132026-07-14 16:49:10YA-101 Receives Orphan Drug Designation in Japan, Following U.S. FDA Fast Track, Advancing Global Development PlansNew Collaborations and Agreements
https://dasherneuroscience.com/wp-content/uploads/2026/03/favicon.png
512
512
tflo
/wp-content/uploads/2026/03/LOGO_Primary.png
tflo2026-04-14 14:54:582026-07-14 16:47:47Dasher Neuroscience, Taiwan’s First: AI-Developed Drug Prioritized by iLCT for Parkinson’s Disease Development; Signs MOUs with Australia and New Zealand to Expand Clinical Reach
https://dasherneuroscience.com/wp-content/uploads/2026/04/IMG_4346-scaled.jpeg
2560
1920
tflo
/wp-content/uploads/2026/03/LOGO_Primary.png
tflo2026-04-07 16:40:362026-07-14 16:50:32Dasher Neuroscience Signs MOU with Norwegian Research Center to Join the Platform Trial HYDRA and Advance AI-Driven Parkinson’s Drug Development in Europe